Elanco Animal Health (NYSE:ELAN) Announces Earnings Results

Elanco Animal Health (NYSE:ELAN) posted its earnings results on Wednesday. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06, Zacks reports. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the company posted $0.13 earnings per share. Elanco Animal Health’s revenue for the quarter was up 10.4% compared to the same quarter last year. Elanco Animal Health updated its FY 2025 guidance to 0.910-0.940 EPS and its Q4 2025 guidance to 0.090-0.120 EPS.

Elanco Animal Health Stock Down 0.6%

NYSE:ELAN traded down $0.12 during mid-day trading on Thursday, hitting $21.48. The stock had a trading volume of 6,668,755 shares, compared to its average volume of 5,929,614. The stock has a 50-day simple moving average of $20.05 and a two-hundred day simple moving average of $16.03. The company has a market capitalization of $10.67 billion, a PE ratio of 24.98, a PEG ratio of 3.51 and a beta of 1.71. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $22.98. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61.

Analyst Ratings Changes

A number of research analysts have commented on ELAN shares. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research report on Thursday, July 17th. UBS Group boosted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds have recently added to or reduced their stakes in ELAN. Geneos Wealth Management Inc. increased its stake in Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Elanco Animal Health by 26.4% during the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock worth $91,000 after acquiring an additional 1,332 shares during the last quarter. Cresset Asset Management LLC lifted its holdings in shares of Elanco Animal Health by 12.8% during the second quarter. Cresset Asset Management LLC now owns 11,338 shares of the company’s stock worth $162,000 after purchasing an additional 1,287 shares during the period. Empowered Funds LLC lifted its holdings in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after purchasing an additional 4,121 shares during the period. Finally, Vident Advisory LLC lifted its holdings in shares of Elanco Animal Health by 14.5% during the second quarter. Vident Advisory LLC now owns 16,952 shares of the company’s stock worth $242,000 after purchasing an additional 2,144 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.